Mendus - Management update on vididencel in AML
Mendus has provided an update on its development plans for its lead cancer vaccine, vididencel, primarily targeting the acute myeloid leukaemia (AML) maintenance setting. Management expects to share updated survival data in Q423 for its ongoing ADVANCE II trial, consistent with prior guidance; vididencel is being investigated as a monotherapy for AML maintenance. Management also intends to maximise the potential of vididencel by preparing for a Phase II combination study with Onureg, the only approved AML maintenance drug to date. We view the company’s previously disclosed strategy of prioritising a combination study as a sensible and logical step forward for vididencel’s clinical development, and continue to believe that combination treatment regimens (as noted in our AML thematic report) will be important for clinical breakthroughs in oncology. Therefore, the anticipated H223 commencement of the planned Phase II trial represents a key near-term milestone for Mendus, in our view.Immunicum AB is a Sweden-based company principally engaged in the biopharmaceutical sector. The Company develops immunotherapy for therapeutic treatment of cancer and infectious diseases. The Company uses therapeutic vaccines to treat an already existing disease and is thus given to the already sick patients; therapeutic cancer vaccines administered to patients in order to delay or stop tumor cell growth, shrink tumors, prevent relapse, or to kill cancer cells that could not be eliminated with other treatments. The Company has several technology platforms, such as The Combig, Intuvax@, Subcuvax@ and The CD70, among others. The Company has several projects which are related to kidney cancer and liver cancer, among others.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.